Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?
Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230.
Weill Cornell Medical College, New York, New York.|Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexandra
A
Snyder
Weill Cornell Medical College, New York, New York. wolcokj@mskcc.org.|Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.|Immunology Program, Sloan Kettering Institute, New York, New York.|Parker Institute for Cancer Immunotherapy and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, New York.
Jedd D
JD
Wolchok
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D004257:DNA Polymerase II / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018095:Germ-Line Mutation / Q000235:genetics; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000096:biosynthesis; D000075223:Poly-ADP-Ribose Binding Proteins; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000235:genetics*
D061067:Antibodies, Monoclonal, Humanized; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D000075223:Poly-ADP-Ribose Binding Proteins; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab; D004257:DNA Polymerase II; C119525:POLE protein, human